Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Apr-Jun;5(2):200-7.
doi: 10.1080/10903120190940137.

Subcutaneous epinephrine in the prehospital setting

Affiliations
Review

Subcutaneous epinephrine in the prehospital setting

B Safdar et al. Prehosp Emerg Care. 2001 Apr-Jun.

Abstract

Objectives: To outline current practice regarding the prehospital use of subcutaneous epinephrine, and systematically review the existing literature to determine the level of support for its use in the elderly. Many health care personnel are reluctant to administer subcutaneous epinephrine for potentially life-threatening conditions such as asthma and anaphylaxis in older patients. This sytematic review examined the following focused question: "For older patients not known to have coronary artery disease, does administration of subcutaneous epinephrine carry a significant enough risk of cardiovascular side effects to mandate age as a relative contraindication to self-administration or emergency medical services administration in the prehospital setting?"

Methods: The MEDLINE and Health Star databases were searched to identify studies evaluating the use of subcutaneous epinephrine in the treatment of asthma and anaphylaxis. Bibliographies from included studies, known reviews, and textbooks were examined to identify additional studies. The strength of evidence presented in each study was assessed in accordance with the classification system proposed by the American Heart Association's Emergency Cardiovascular Care Committee.

Results: The review of the literature revealed only three case reports (level VII evidence) that record adverse reactions of epinephrine when used for anaphylaxis and allergy, while several level III and V studies found no adverse effects when used for asthma. No controlled trials documenting adverse effects were found.

Conclusions: The authors did not find significant evidence to contraindicate the use of subcutaneous epinephrine in older patients who are not known to have coronary artery disease, who present with either asthma or allergic reactions.

PubMed Disclaimer

Similar articles

Cited by

  • A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).
    Li X, Ma Q, Yin J, Zheng Y, Chen R, Chen Y, Li T, Wang Y, Yang K, Zhang H, Tang Y, Chen Y, Dong H, Gu Q, Guo D, Hu X, Xie L, Li B, Li Y, Lin T, Liu F, Liu Z, Lyu L, Mei Q, Shao J, Xin H, Yang F, Yang H, Yang W, Yao X, Yu C, Zhan S, Zhang G, Wang M, Zhu Z, Zhou B, Gu J, Xian M, Lyu Y, Li Z, Zheng H, Cui C, Deng S, Huang C, Li L, Liu P, Men P, Shao C, Wang S, Ma X, Wang Q, Zhai S. Li X, et al. Front Pharmacol. 2022 Mar 28;13:845689. doi: 10.3389/fphar.2022.845689. eCollection 2022. Front Pharmacol. 2022. PMID: 35418863 Free PMC article.
  • Factors associated with repeated use of epinephrine for the treatment of anaphylaxis.
    Manivannan V, Campbell RL, Bellolio MF, Stead LG, Li JT, Decker WW. Manivannan V, et al. Ann Allergy Asthma Immunol. 2009 Nov;103(5):395-400. doi: 10.1016/S1081-1206(10)60358-4. Ann Allergy Asthma Immunol. 2009. PMID: 19927537 Free PMC article.

LinkOut - more resources